Literature DB >> 27043884

Determinants and frequency of irritable bowel syndrome in a German sample.

A Althaus, W Broicher, P Wittkamp1, V Andresen2, A W Lohse3, B Löwe1.   

Abstract

BACKGROUND: To date there is no study that has estimated the prevalence of irritable bowel syndrome (IBS) in Germany according to the current Rome III criteria. The aim of the present study was to investigate the prevalence of IBS in a non-clinical German sample. Furthermore, we investigated the association of IBS with socio-demographic and psychological risk factors.
METHODS: Baseline data from a prospective cohort study were analysed, including the IBS Module of the Rome III Diagnostic Questionnaires and validated psychometric scales including the Patient Health Questionnaire-15 (PHQ-15), the Big Five Inventory (BFI), the Perceived Stress Questionnaire (PSQ-5), and the Whiteley-Index (WI-7). The study population was compared to the German general population to appraise its representativeness. Multivariate logistic regression analyses were performed to identify possible risk factors associated with IBS.
RESULTS: Between January 2011 and September 2012, 2419 persons participated (female 54.0 %, mean age 37.4 ± 14.9 years). According to the Rome III criteria, 401 participants (16.6 %) suffered from IBS. Five predictors were independently associated with IBS: previous traveller's diarrhoea infection (OR = 1.76; 95 % CI = 1.34 to 2.31), higher somatic symptom burden (OR = 1.15; 95 % CI = 1.07 to 1.23), increased level of hypochondriasis (OR = 2.04; 95 % CI = 1.54 to 2.70), increased vulnerability to diarrhoea under stress (OR = 3.88; 95 % CI = 3.21 to 4.68) and perceived stress (OR = 1.43; 95 % CI = 1.04 to 1.99).
CONCLUSIONS: Our analyses yielded a relatively high IBS prevalence estimate, compared to studies published more than ten years ago. This might partially be explained by the fact that the time criterion of the Rome III criteria (at least 3 days/month in last 3 months) is more inclusive compared to the time criterion of the Rome II criteria (at least 12 weeks, which need not be consecutive, in the preceding 12 months). © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2016        PMID: 27043884     DOI: 10.1055/s-0041-106856

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  5 in total

1.  Predictors of Health-related Quality of Life in Irritable Bowel Syndrome Patients Compared With Healthy Individuals.

Authors:  Raymond Addante; Bruce Naliboff; Wendy Shih; Angela P Presson; Kirsten Tillisch; Emeran A Mayer; Lin Chang
Journal:  J Clin Gastroenterol       Date:  2019-04       Impact factor: 3.062

2.  The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome.

Authors:  Winfried Häuser; Ursula Marschall; Peter Layer; Thomas Grobe
Journal:  Dtsch Arztebl Int       Date:  2019-07-08       Impact factor: 5.594

3.  Persistence of gastrointestinal symptoms in irritable bowel syndrome and ulcerative colitis: study protocol for a three-arm randomised controlled trial (SOMA.GUT-RCT).

Authors:  Bernd Löwe; Yvonne Nestoriuc; Viola Andresen; Eik Vettorazzi; Antonia Zapf; Sina Hübener; Kerstin Maehder; Luisa Peters; Ansgar W Lohse
Journal:  BMJ Open       Date:  2022-06-14       Impact factor: 3.006

Review 4.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

5.  The Development of Irritable Bowel Syndrome: A Prospective Community-Based Cohort Study.

Authors:  Bernd Löwe; Ansgar Lohse; Viola Andresen; Eik Vettorazzi; Matthias Rose; Wiebke Broicher
Journal:  Am J Gastroenterol       Date:  2016-07-05       Impact factor: 10.864

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.